Evidence map›Paper›PMID 40591079›Full record

ArticleDiscover oncology2025

The impact of vascular endothelial growth factor on oral squamous cell carcinoma through dendritic cell induction and facilitation of tumor immune tolerance.

Peng Zhang, Yue Xu, Bolei Cai, Jiaqiang Xu, Tao Wang, Hongyan Xu

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peng Zhang *Department of Stomatology, Shaanxi Provincial People's Hospital, No.256 Youyi West Road, Xi'an, 710000, Shaanxi, China.
Yue Xu *Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, 710000, Shaanxi, China.
Bolei CaiAir Force Medical University Stomatological Hospital, No.256 Youyi West Road, Xi'an, 710000, Shaanxi, China.
Jiaqiang XuDepartment of Stomatology, People's Hospital of Ningjin County, Dezhou, 253400, Shandong, China.
Tao WangDepartment of Stomatology, Shaanxi Provincial People's Hospital, No.256 Youyi West Road, Xi'an, 710000, Shaanxi, China. wangtao171@126.com.
Hongyan XuDepartment of Stomatology, Shaanxi Provincial People's Hospital, No.256 Youyi West Road, Xi'an, 710000, Shaanxi, China. KY14725836@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe primary goal of this research is to gain a deeper understanding of the intricate role that VEGF plays in creating an immunologically tolerant milieu in cases of OSCC or oral squamous cell carcinoma. Examining how VEGF affects the behavior and functionality of dendritic cells (DCs). Through an examination of the interactions among VEGF, DCs, and the tumor microenvironment.

methodsThis study investigated the expression of the immunosuppressive markers IDO and programmed cell death ligand 1 (PD-L1) in DCs under the effect of VEGF employing real-time PCR (RT-PCR), flow cytometry and Western blot (WB). Additionally, mixed lymphocyte reactions and tumor cell cytotoxicity assays were conducted to assess functional changes in DCs.

resultsVEGF exposure led to an upregulation of IDO and PD-L1 in DCs, coupled with reduced T-cell proliferation and altered immune responses in the tumor microenvironment. In vivo studies using mice models further substantiated the role of VEGF in enhancing tumor immune tolerance.

conclusionOur findings elucidate the crucial role of VEGF in OSCC progression by modulating DC function, offering new insights into potential immunotherapeutic strategies targeting VEGF-mediated pathways.

Indexed as

Tumor microenvironment programmed cell death ligand 1Vascular endothelial growth factor dendritic cells oral squamous cell carcinoma

Identifiers

PMID40591079
PMCPMC12214178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.